Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 19 of 25, showing 5 Applications out of 121 total, starting on record 91, ending on 95

# Protocol No Study Title Investigator(s) & Site(s)

91.

ECCT/16/08/03   IMPAACT 2001
    A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed project
 
View

92.

ECCT/16/07/05   HESTIA 1
    Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county)
3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county)
4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county)
 
View

93.

ECCT/16/06/01   P1115
    Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
KEMRI WALTER REED PROJECT KERICHO
 
View

94.

ECCT/16/05/03   Clinical trial of neem & coconut oils for tungiasis
    Phase IIA, randomised controlled trial of a locally-made, herbal remedy (neem & coconut oil) for treatment of jiggers (Tunga penetrans)   
Principal Investigator(s)
1. Ulrike Fillinger
Site(s) in Kenya
Dabaso Tujengane CBO
 
View

95.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View